The Latest
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
BeOne Medicines grabbed an option to acquire an antibody from HuaHui Health that acts on three known cancer targets: PD-1, CTLA-4 and VEGF.
Updated 20 hours ago -
Elizabeth Regan/BioPharma Dive
Chiesi to buy KalVista in $1.9B deal for rare disease drug
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
-
Courtesy of Teva Pharmaceutical
Brain drug revivalTeva nabs experimental Tourette drug in $700M Emalex buyout
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
-
Getty Images
News roundupFDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multiple myeloma drug.
-
Permission granted by Nasdaq, Inc. / Vanja Savic
Deep Dive // Emerging biotechBiotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
-
Getty Images
Pfizer deals extend patent life for a top-selling rare disease drug
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
-
Courtesy of Boehringer Ingelheim
Obesity drugsBoehringer dual-acting obesity shot hits mark in Phase 3 trial
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
LEO Pharma is paying $50 million upfront to acquire Replay, a privately held biotech developing gene therapies for rare skin conditions.
Updated 20 hours ago -
Getty Images
Emerging biotechCoultreon banks $125M to support testing of former Galapagos immune drug
Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.
-
Getty Images
News roundup
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
-
Getty Images
Veradermics soars on positive data for baldness treatment
The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medications.
-
Permission granted by Intellia Therapeutics
Gene editingIntellia CRISPR drug succeeds in late-stage study against rare swelling disorder
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.
-
Permission granted by Ajax Therapeutics
Lilly to buy startup Ajax in bid for a better JAK drug
Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Hemab Therapeutics and Seaport Therapeutics on Thursday rounded out a busy week for IPOs that has pushed the total raised by newly public biotech companies in 2026 to nearly $3.2 billion.
Updated 8 hours ago -
Getty Images
Oruka surges as long-acting psoriasis drug shows early promise
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
-
Courtesy of Sanofi
Sanofi MS drug rejected in US gets an endorsement in Europe
Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory approval.
-
Permission granted by Roche
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
-
Getty Images
FDA approves Regeneron’s hearing loss gene therapy
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients at no cost.
-
Getty Images
News roundup
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.
Updated April 24, 2026 -
Getty Images
Sanofi posts upbeat sales as R&D pressure builds
A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.
-
Permission granted by Hwang lab
Revolution drug shows promise in early pancreatic cancer
The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.
-
Getty Images
An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”
-
Maddie Meyer via Getty Images
VaccinesModerna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.
-
Getty Images
News roundup
Merck adds to pharma’s AI push; Roche details MS drug results
Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alliance.
-
Permission granted by Serif Biosciences
Startup launchesSerif, Flagship’s latest biotech, aims to make a new kind of genetic medicine
The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.
